<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03341403</url>
  </required_header>
  <id_info>
    <org_study_id>2017-248</org_study_id>
    <secondary_id>B707201733638</secondary_id>
    <nct_id>NCT03341403</nct_id>
  </id_info>
  <brief_title>Effect of a Synbiotic &quot;Probiotical® &quot; in Asthma</brief_title>
  <official_title>Assessment of the Impact of a Dietary Supplement Synbiotic &quot;Probiotical ®&quot; in Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Liege</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Union</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital of Liege</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a randomized double blind placebo control study. One hundred severe asthmatic patients
      will receive &quot;Probiotical ®&quot; each day during 3 months and will be evaluated before and 1-3-6
      months after in order to assess the impact of the synbiotic on the lung function, the exhaled
      nitric oxide value, the inflammatory blood and sputum profiles, the bronchial reactivity, the
      microvascular health and the quality of life and asthma control. The hypothesis is that, as
      these patients are not optimally controlled, the synbiotic could have an impact by decreasing
      the inflammation state at local and systemic level and then improve the quality of life and
      the asthma control. Indeed, synbiotic have been shown to possess beneficial effects on the
      immune system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Thirty percent of asthmatic patients are not well controlled even with an optimal treatment.
      There is then a need for new therapeutics allowing a better asthma control. Synbiotic
      (association of probiotics and prebiotics) have been shown to have anti-inflammatory
      properties as well as immunomodulatory activities. Moreover, synbiotic appeared to be very
      well tolerated and safe.

      One hundred severe asthmatic patients (ACQ&gt; 1.5 and beclomethasone &gt; 200 µg per day) will
      receive &quot;Probiotical ®&quot; (3 pills a day, content: Lactobacillus, Bifidobacterium et
      Streptococcus thermophilus, 18 billion of bacteria per pill) or a placebo during 3 months.

      They will be evaluated before and 1-3-6 months after the first administration and different
      tests will be realized:

        -  lung function tests (spirometry, lung volumes, diffusing capacity)

        -  exhaled nitric oxide value (FeNo, linked to airway eosinophilia)

        -  blood tests: leucocyte count, c reactive protein, fibrinogen. Plasma and serum will be
           kept for inflammatory mediators measurements.

        -  sputum induction: leucocyte count and mediators measurements using the sputum
           supernatant and sputum cells.

        -  bronchial reactivity (bronchial challenge test)

        -  microvascular health: to assess the glycocalyx state, see: http://glycocheck.com/ for
           details.

        -  questionnaires: asthma control test (ACT), asthma control questionnaire (ACQ), asthma
           quality of life questionnaire (AQLQ ).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 17, 2017</start_date>
  <completion_date type="Anticipated">January 31, 2020</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>randomized double blind placebo control study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Only Phacobel which provide the pills will have the knowledge of the pills codes.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>ACQ improvement</measure>
    <time_frame>before the administration and 1-3-6 months after the first administration</time_frame>
    <description>improvement of asthma control. Patients are asked to recall how their asthma has been during the previous week and to respond to the symptom and bronchodilator use questions on a 7-point scale (0=no impairment, 6= maximum impairment). The questions are equally weighted and the ACQ score is the mean of the 7 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled). An improvement correspond to a decrease of at least 0.5 compared to the last evaluation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>exhaled nitric oxide value decrease</measure>
    <time_frame>before the administration and 1-3-6 months after the first administration</time_frame>
    <description>measure in ppb with a chemoluminescence analyser</description>
  </secondary_outcome>
  <other_outcome>
    <measure>blood eosinophil count decrease</measure>
    <time_frame>before the administration and 1-3-6 months after the first administration</time_frame>
    <description>in absolute value</description>
  </other_outcome>
  <other_outcome>
    <measure>sputum eosinophil count decrease</measure>
    <time_frame>before the administration and 1-3-6 months after the first administration</time_frame>
    <description>in absolute value</description>
  </other_outcome>
  <other_outcome>
    <measure>sputum eosinophil percentage decrease</measure>
    <time_frame>before the administration and 1-3-6 months after the first administration</time_frame>
    <description>in percentage</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Synbiotic group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>severe asthmatic patients (ACQ&gt; 1.5 and beclomethasone &gt; 200 µg per day) will receive &quot;Probiotical ®&quot; (3 pills a day, content: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill) during 3 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>severe asthmatic patients (ACQ&gt; 1.5 and beclomethasone &gt; 200 µg per day) will receive a placebo (3 pills a day) during 3 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotical®</intervention_name>
    <description>&quot;Probiotical&quot; is composed of: Lactobacillus, Bifidobacterium et Streptococcus thermophilus, 18 billion of bacteria per pill.</description>
    <arm_group_label>Synbiotic group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>pills containing placebo</description>
    <arm_group_label>Placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  severe asthma (ACQ &gt;1.5 and treatment = minimum 200 µg beclomethasone) and stable
             treatment for at least 3 months.

        Exclusion Criteria:

          -  treatment not stable

          -  exacerbation state

          -  infection
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Renaud Louis, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU-ULG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Renaud Louis, Prof.</last_name>
    <phone>003243667881</phone>
    <email>r.louis@chu.ulg.ac.be</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Catherine C Moermans, PhD</last_name>
    <phone>003243664916</phone>
    <email>c.moermans@chu.ulg.ac.be</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital of Liege</name>
      <address>
        <city>Liege</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renaud Louis, Prof.</last_name>
      <phone>003243667881</phone>
      <email>r.louis@chu.ulg.ac.be</email>
    </contact>
    <contact_backup>
      <last_name>Catherine Moermans, PhD</last_name>
      <phone>003243664916</phone>
      <email>c.moermans@chu.ulg.ac.be</email>
    </contact_backup>
    <investigator>
      <last_name>Renaud Louis</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence Schleich</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monique Henket</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Virginie Paulus</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie Graff</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine Moermans</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Ziant</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>http://glycocheck.com/</url>
    <description>Glycocheck website</description>
  </link>
  <link>
    <url>https://www.interregemr.eu/projects/healthyaging-en</url>
    <description>interreg Euregio Meuse Rhine project</description>
  </link>
  <link>
    <url>http://www.phacobel.be/index.php?lang=en&amp;sec=3&amp;id=2</url>
    <description>Probiotical from Phacobel</description>
  </link>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 8, 2017</study_first_submitted>
  <study_first_submitted_qc>November 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>January 19, 2018</last_update_submitted>
  <last_update_submitted_qc>January 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 23, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital of Liege</investigator_affiliation>
    <investigator_full_name>Renaud Louis</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>severe asthma</keyword>
  <keyword>synbiotic</keyword>
  <keyword>immunomodulation</keyword>
  <keyword>sputum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

